Pharmaceuticals

#Biopharmaceuticals #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug innovation #Immunology / Virology & Vaccines #Pharma #Pharmaceuticals #Vaccines

Integration at its best: Dalton Pharma outlines its CDMO expertise

Dalton Pharma Services, a contract development and manufacturing organisation (CDMO) offers expertise in drug discovery, formulation and process development, custom synthesis, and GMP manufacturing services. Lu Rahman spoke to CEO, Peter Pekos about the company’s ongoing expertise. LR: The company has experience supplying the needs of the orphan drug field… Read More

#Exclusive Content #News #Opinion

#Antibodies #Assays #Pharmaceuticals #Small molecules

Synthesising new solutions for small molecule antibodies

Toni Rogers and David Bunka, Aptamer Group discuss how newer antibody alternative technologies are demonstrating significant developments, offering novel solutions to improve success, decrease project timelines and produce innovative low-cost assays to small molecule targets across many sectors. Small molecules are ubiquitous in our environment, from toxins and heavy metals… Read More

#Editor's Choice #Exclusive Content #News

#Drug development #Drug discovery #Generics #Pharmaceuticals

Drug discovery and India: the future looks bright

As the world’s largest generic producer how far advanced is India’s drug discovery push and where does it stand on the global stage? Lu Rahman explores. India has become a key player in the global pharmaceutical sector. The value of its part in this industry is expected to reach $120… Read More

#Covid-19 #Editor's Choice #Exclusive Content #Intelligence #Market Reports #News

#Drug design #Pharma #Pharmaceuticals #Regulatory

Biotech consultancy has recruitment drive following surge in demand

Turnover at pharmaceutical and biotech product development consultancy Boyds has surged by 25% as demand for its specialist services continues to grow. The company has added seven regulatory and medical affairs experts to its team, and is now launching an even larger recruitment drive creating up to ten new roles… Read More

#News

#Compounds #Drug discovery #Pharmaceuticals

A guide to fragment-based drug discovery

Fragment-based drug discovery (FBDD) is one of the most popular approaches for finding lead compounds and it is becoming more widely adopted by pharma companies. FBDD is the solution researchers turn to when faced with challenging targets that call for compound libraries that offer more diverse molecules — especially from… Read More

#News

#Biotechnology #Cell and gene therapy #Pharmaceuticals

WuXi AppTec acquires OXGENE to strengthen cell and gene therapy service

WuXi AppTec, provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, has completed the acquisition of OXGENE, a UK-based contract research and development organisation that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the… Read More

#Editor's Choice #News

#Big pharma #Medical devices #Pharmaceuticals

The rise of neurotech devices and the moment of truth for the pharma industry

by Tiago R. Felix Simply put, drugs alone are not, and will probably not be, an effective and safe treatment for most cases of nervous system disorders (NSDs). However, both society and the pharmaceutical industry seem to have so far largely overlooked the most promising alternative to drugs in the… Read More

#News

#Life sciences #Pharmaceuticals #Research & development

Pistoia Alliance Conference: Collaborative R&D in Action

The Pistoia Alliance will be holding a free virtual conference which will include a series of  discussions with top pharma R&D leaders on the big issues facing our industry. Collaborative R&D in Action, April 20-21 & 23, provides a platform for R&D stakeholders to collaborate, learn and network across the… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Clinical trials #Drug discovery #Pharmaceuticals #Rare disease #Therapeutics

The move towards patient-powered, data-driven rare disease drug discovery

By Rayne Rodgers, Vice President and Executive Director of MOVR for Muscular Dystrophy Association (MDA), and Sharon Hesterlee MDA’s Executive Vice President and Chief Research Officer. As an umbrella organisation representing those living with more than 40 types of neuromuscular disorders, the Muscular Dystrophy Association (MDA) contributes significantly to innovations… Read More

#Editor's Choice #Exclusive Content #News

#Pharmaceuticals

Pfizer head set for ABPI President role

The Association of the British Pharmaceutical Industry (ABPI) has announced that Ben Osborn, UK Country Manager, Pfizer, has been elected as as President-elect of the ABPI. Osborn has over twenty years of experience across a range of leadership roles at Pfizer, where he began his career in 1998. Prior to… Read More

#News

#Biotherapeutics #Microbiome #Oncology #Pharmaceuticals

4D pharma collaboration with Merck and Pfizer for urothelial carcinoma

4D pharma, a pharmaceutical company looking at the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, has announced a clinical trial collaboration and supply agreement with Merck and Pfizer for BAVENCIO(R) (avelumab), the immunotherapy approved as a first-line maintenance treatment for patients with… Read More

#Cancer Research #Editor's Choice #News

#AI / data analytics / healthtech / informatics #Pharmaceuticals

New AI-powered platform aims to revolutionise pharma marketing

PatientMetRx, an AI-powered social intelligence service from UK data tech company Talking Medicines, has been launched, to give the drug brands insights on patient experience on a scale and depth never previously possible. Specialists in social intelligence for the pharmaceutical industry, Talking Medicines developed PatientMetRx to provide a systematic way… Read More

#News

#Metabolomics #Pharmaceuticals #Research & development

Boosting pharmaceutical research with microbiome data

Microbiome-based evidence is set to drive understanding of how drugs interact with human ‘host’ environments, helping devise more targeted treatments and create business opportunities, reports Anthony Finbow, CEO of Eagle Genomics. The microbiology of the drug recipient impacts their immune response, allergic responses and more. Increasingly, life sciences R&D is… Read More

#Editor's Choice #Exclusive Content #News #Trends & Analysis

#Biotechnology #Pharmaceuticals

Reach Separations pushes expansion plans and alliance with NovAliX 

Purification specialists Reach Separations and French drug discovery CRO, NovAliX, have entered into an alliance to develop supercritical fluid chromatography (SFC) capabilities at the NovAliX facility near Strasbourg. Formed in support of Reach Separations’ strategy to grow its European presence, and in response to a sustained rise in demand for… Read More

#News

#AI / data analytics / healthtech / informatics #Biologics #Drug discovery #Pharmaceuticals

Is the pharmaceutical industry ready to listen directly to patients?

Dr Elizabeth Fairley, COO and co-founder of social intelligence company Talking Medicines, explains how technology has shaped the drug landscape and why actually listening to patients might be the breakthrough the industry needs. There are more drugs on the market today than ever before and the drug pipeline is massively… Read More

#Editor's Choice #News #Opinion